Sign in

CIK 0001374690

  • Non-accelerated filer
  • Smaller reporting company

Larimar Therapeutics, Inc.

Sign in to watch
Ticker
LRMR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
203857670
Phone
+1 844-511-9056
Business address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
Former names
ZAFGEN, INC., ZAFGEN INC
  1. 4 Derivatives Options or other derivatives
  2. 3 Insider Initial Statement of Ownership
  3. 4 Open-market buy 10% owner bought 64,545 shares at $6.25 ($403,187)
  4. 4 Open-market buy 10% owner bought 267,493 shares at an average $6.02 ($1,609,668)
  5. 3 Insider Initial Statement of Ownership
  6. 4 Grant or award Director acquired 8,849 shares (grant or award)
  7. 4 Derivatives Options or other derivatives
  8. 4 Grant or award Director acquired 4,424 shares (grant or award)
  9. 4 Grant or award Director acquired 4,424 shares (grant or award)
  10. 4 Exercise or conversion Chief Executive Officer acquired 10,000 shares (option exercise)
  11. 4 Grant or award Director acquired 899 shares (grant or award)
  12. 4 Derivatives Options or other derivatives
  13. 4/A Open-market sale Chief Medical Officer sold 39,407 shares at $40.00 ($1,576,280)
  14. 4/A Open-market sale Chief Medical Officer sold 593 shares at $40.00 ($23,720)
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 3 Insider Initial Statement of Ownership
  18. 3 Insider Initial Statement of Ownership
  19. 4 Open-market sale Director sold 136,579 shares at an average $43.90 ($5,995,403)
  20. 4 Exercise or conversion Chief Executive Officer acquired 10,500 shares (option exercise)

Page 11 of 14 · 273 filings